Baldetorp B - Search Results

1

ERBB2 amplification in breast cancer with a high rate of proliferation.

Borg A, Baldetorp B, Fernö M, Killander D, Olsson H, Sigurdsson H. Borg A, et al. Among authors: baldetorp b. Oncogene. 1991 Jan;6(1):137-43. Oncogene. 1991. PMID: 1671531

2

c-myc amplification is an independent prognostic factor in postmenopausal breast cancer.

Borg A, Baldetorp B, Fernö M, Olsson H, Sigurdsson H. Borg A, et al. Among authors: baldetorp b. Int J Cancer. 1992 Jul 9;51(5):687-91. doi: 10.1002/ijc.2910510504. Int J Cancer. 1992. PMID: 1612775

3

Flow cytometric DNA index and S-phase fraction in breast cancer in relation to other prognostic variables and to clinical outcome.

Fernö M, Baldetorp B, Borg A, Olsson H, Sigurdsson H, Killander D. Fernö M, et al. Among authors: baldetorp b. Acta Oncol. 1992;31(2):157-65. doi: 10.3109/02841869209088897. Acta Oncol. 1992. PMID: 1622630

4

Proliferation and DNA ploidy in malignant breast tumors in relation to early oral contraceptive use and early abortions.

Olsson H, Ranstam J, Baldetorp B, Ewers SB, Fernö M, Killander D, Sigurdsson H. Olsson H, et al. Among authors: baldetorp b. Cancer. 1991 Mar 1;67(5):1285-90. doi: 10.1002/1097-0142(19910301)67:5<1285::aid-cncr2820670502>3.0.co;2-q. Cancer. 1991. PMID: 1991290

5

Flow cytometry in primary breast cancer: improving the prognostic value of the fraction of cells in the S-phase by optimal categorisation of cut-off levels.

Sigurdsson H, Baldetorp B, Borg A, Dalberg M, Fernö M, Killander D, Olsson H, Ranstam J. Sigurdsson H, et al. Among authors: baldetorp b. Br J Cancer. 1990 Nov;62(5):786-90. doi: 10.1038/bjc.1990.380. Br J Cancer. 1990. PMID: 2245171 Free PMC article.

6

Indicators of prognosis in node-negative breast cancer.

Sigurdsson H, Baldetorp B, Borg A, Dalberg M, Fernö M, Killander D, Olsson H. Sigurdsson H, et al. Among authors: baldetorp b. N Engl J Med. 1990 Apr 12;322(15):1045-53. doi: 10.1056/NEJM199004123221505. N Engl J Med. 1990. PMID: 2320064 Free article.

7

Flow cytometry DNA ploidy and number of cell populations in the primary breast cancer and their correlation to the prognosis.

Ewers SB, Baldetorp B, Killander D, Långström E. Ewers SB, et al. Among authors: baldetorp b. Acta Oncol. 1989;28(6):913-8. doi: 10.3109/02841868909092331. Acta Oncol. 1989. PMID: 2611041

8

Recurrence-free survival in breast cancer improved by adjuvant tamoxifen--especially for progesterone receptor positive tumors with a high proliferation.

Fernö M, Baldetorp B, Bendahl PO, Borg A, Ewers SB, Olsson H, Rydén S, Sigurdsson H, Killander D. Fernö M, et al. Among authors: baldetorp b. Breast Cancer Res Treat. 1995;36(1):23-34. doi: 10.1007/BF00690181. Breast Cancer Res Treat. 1995. PMID: 7579503 Clinical Trial.

9

Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. South Sweden Breast Cancer Group.

Fernö M, Baldetorp B, Borg A, Brouillet JP, Olsson H, Rochefort H, Sellberg G, Sigurdsson H, Killander D. Fernö M, et al. Among authors: baldetorp b. Eur J Cancer. 1994;30A(14):2042-8. doi: 10.1016/0959-8049(94)00307-q. Eur J Cancer. 1994. PMID: 7857700

10

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer.

Borg A, Baldetorp B, Fernö M, Killander D, Olsson H, Rydén S, Sigurdsson H. Borg A, et al. Among authors: baldetorp b. Cancer Lett. 1994 Jun 30;81(2):137-44. doi: 10.1016/0304-3835(94)90194-5. Cancer Lett. 1994. PMID: 7912163 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

148 results

Search Page

Filters